Literature DB >> 7855619

Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

A Yagoda1, B Abi-Rached, D Petrylak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7855619

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  63 in total

Review 1.  Immunotherapy for renal carcinoma: theoretical basis and current standard of care.

Authors:  P A Vasey
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

Review 2.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

3.  Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review.

Authors:  Christina Canil; Sebastien Hotte; Linda A Mayhew; Tricia S Waldron; Eric Winquist
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

4.  Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.

Authors:  George E Manoukian; Nizar M Tannir; Eric Jonasch; Wei Qiao; Tamara M Haygood; Shi-Ming Tu
Journal:  Clin Genitourin Cancer       Date:  2011-10-01       Impact factor: 2.872

5.  Targeted therapy for renal cell carcinoma: a new treatment paradigm.

Authors:  Thomas E Hutson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-07

6.  Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.

Authors:  Sylvie Negrier; Frédéric Gomez; Jean-Yves Douillard; Alain Ravaud; Christine Chevreau; Murielle Buclon; David Perol; Christine Lasset; Bernard Escudier
Journal:  World J Urol       Date:  2005-02-12       Impact factor: 4.226

7.  Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.

Authors:  Ivette A G Deckers; Leo J Schouten; Leander Van Neste; Iris J H van Vlodrop; Patricia M M B Soetekouw; Marcella M L L Baldewijns; Jana Jeschke; Nita Ahuja; James G Herman; Piet A van den Brandt; Manon van Engeland
Journal:  Clin Cancer Res       Date:  2015-04-22       Impact factor: 12.531

8.  Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.

Authors:  Vitaly Margulis; Surena F Matin; Nizar Tannir; Pheroze Tamboli; Yu Shen; Marisa Lozano; David A Swanson; Eric Jonasch; Christopher G Wood
Journal:  Urology       Date:  2008-10-31       Impact factor: 2.649

Review 9.  The role of functional imaging in the era of targeted therapy of renal cell carcinoma.

Authors:  Margarita Braunagel; Anno Graser; Maximilian Reiser; Mike Notohamiprodjo
Journal:  World J Urol       Date:  2013-04-16       Impact factor: 4.226

Review 10.  The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma.

Authors:  Antonio Romo de Vivar Chavez; Michael E de Vera; Xiaoyan Liang; Michael T Lotze
Journal:  Med Oncol       Date:  2009-01-16       Impact factor: 3.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.